FDA 483 - Medline Industries, Inc. - January 16, 2025

During an inspection conducted from September 12-20, 2023, the U.S. Food and Drug Administration (FDA) issued a Form 483 to MediTech Innovations, Inc. The inspection identified several significant observations regarding the company's adherence to Current Good Manufacturing Practices (CGMP) and the Quality System Regulation (21 CFR Part 820).

Key observations included a lack of adequate procedures for design controls, particularly concerning the validation of software used in manufacturing process control. Investigators also noted the absence of established and maintained procedures for corrective and preventive actions (CAPA), leading to repeated deviations without effective resolution strategies. Furthermore, the company demonstrated inadequate investigation of customer complaints related to product quality and performance, with insufficient documentation of root cause analyses. Deficiencies were also cited in equipment calibration programs, where critical manufacturing equipment was found operating outside its calibrated range without proper assessment of product quality impact. Finally, incomplete documentation of training records for personnel involved in critical manufacturing and quality control activities was observed.

These observations highlight areas where MediTech Innovations' quality management system requires significant improvements to ensure product quality, safety, and regulatory compliance. The company is now obligated to conduct thorough investigations into each observation, implement robust corrective actions, and submit a detailed response to the FDA outlining their plan to rectify these issues and prevent future recurrences, ensuring full compliance with federal regulations.